Table 2 Determinants of positive antibody response after dual COVID-19 vaccine in patients with CLL
Variable | Univariate analysis | Multivariate analysis (n = 459) | ||
|---|---|---|---|---|
Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
Age (increasing) | 0.99 (0.96 to 1.01) | 0.160 | 0.98 (0.96 to 1.01) | 0.265 |
Sex (male) | 0.64 (0.44 to 0.94) | 0.022 | 0.56 (0.34 to 0.91) | 0.020 |
Vaccine type (Pfizer) | 0.98 (0.67 to 1.44) | 0.919 | 1.16 (0.71 to 1.91) | 0.553 |
Duration of CLL (increasing) | 0.99 (0.99 to 0.99) | < 0.0001 | 0.99 (0.99 to 1.00) | 0.334 |
CLL treatment (yes) | 0.27 (0.19 to 0.41) | < 0.0001 | 0.71 (0.22 to 2.27) | 0.563 |
BTKi treatment (yes) | 0.16 (0.10 to 0.27) | < 0.0001 | 0.20 (0.08 to 0.48) | < 0.0001 |
Previous BTKi treatment (yes) | 0.65 (0.24 to 1.76) | 0.393 | ||
Venetoclax treatment (yes) | 0.19 (0.07 to 0.50) | 0.001 | 0.31 (0.09 to 1.04) | 0.059 |
Previous Venetoclax treatment (yes) | 0.76 (0.13 to 4.60) | 0.767 | ||
Previous chemotherapy (yes) | 0.41 (0.27 to 0.62) | < 0.0001 | 2.24 (0.32 to 15.64) | 0.415 |
Previous anti-CD20 (yes) | 0.43 (0.29 to 0.64) | < 0.0001 | 1.88 (0.52 to 6.82) | 0.338 |
Previous immuno-chemotherapy (yes) | 0.44 (0.29 to 0.66) | < 0.0001 | 0.46 (0.06 to 3.52) | 0.453 |
Planned treatment (yes) | 0.81 (0.26 to 2.52) | 0.716 | ||
History of recurrent infection (yes) | 0.49 (0.33 to 0.74) | 0.001 | 0.96 (0.53 to 1.73) | 0.882 |
Prophylactic antibiotics (yes) | 0.13 (0.06 to 0.29) | < 0.0001 | 0.28 (0.09 to 0.86) | 0.027 |
IVIG (yes) | 0.09 (0.04 to 0.20) | < 0.0001 | 0.34 (0.11 to 1.02) | 0.054 |
IgA (< 0.8 g/L) | 0.19 (0.12 to 0.30) | < 0.0001 | 0.28 (0.16 to 0.48) | < 0.0001 |
IgG (< 6 g/L) | 0.51 (0.35 to 0.76) | 0.001 | 0.83 (0.48 to 1.41) | 0.482 |
IgM (0.5 g/L) | 0.31 (0.21 to 0.47) | < 0.0001 | 0.43 (0.26 to 0.70) | 0.001 |